Revenue + Forward P/E
Edwards Lifesciences Corporation (EW) quarterly revenue and forward P/EForward P/E: 29.6x
RevenueRevenue (est)Forward P/E
Fair value & valuation models
Fair value models are a Plus feature
Upgrade to Plus for the interactive DCF model, valuation bands, and implied-price scenarios.
71% OFF$23.99 $6.99/mo
Ends in23:59:59
Cancel anytime. Secure checkout via Stripe.
Valuation
Market cap
$53.58B
Enterprise value
$45.83B
P/E ratio (TTM)
47.49x
P/S ratio (TTM)
7.31x
P/B ratio
4.61x
EV/Sales
7.04x
EV/EBITDA
29.76x
Dividend yield
0.00%
Income statement (TTM)
Revenue (TTM)
$6.07B
Gross profit (TTM)
$4.74B
Operating income (TTM)
$1.64B
EBITDA (TTM)
$1.43B
Net income (TTM)
$1.07B
Free cash flow (TTM)
$1.33B
Margins & returns
Gross margin
77.98%
Operating margin
28.09%
Profit margin
15.43%
Return on equity
9.71%
Return on assets
7.54%
Per-share metrics
EPS (TTM)
$1.74
Dividend yield
0.00%
Beta
0.85
Capital structure
Cash & equivalents
$2.94B
Total debt
$705.40M
Net debt
$-2.23B
Shares outstanding
575.80M
Financial health
Current ratio
3.72
Debt / equity
0.07
Debt / assets
0.05
Interest coverage
-
| Company | Market cap | P/E | P/S | EV/EBITDA | Div yield |
|---|---|---|---|---|---|
| $1.15T | 42.41x | 15.59x | 34.80x | 0.54% | |
| $628.65B | 30.45x | 6.47x | 20.76x | 1.99% | |
| $439.33B | 127.13x | 7.29x | 30.82x | 2.63% | |
| $368.33B | 27.06x | 0.85x | 16.46x | 2.13% | |
| $355.97B | 23.91x | 4.80x | 15.14x | 2.67% | |
| $328.31B | 36.82x | 4.94x | 19.57x | 2.56% | |
| $53.58B | 47.49x | 7.31x | 29.76x | - |